Metal-organic framework (MOF)/C-dots and covalent organic framework (COF)/C-dots hybrid nanocomposites: Fabrications and applications in sensing, medical, environmental, and energy sectors.

Developing new hybrid materials is critical for addressing the current needs of the world in various fields, such as energy, sensing, health, hygiene, and others. C-dots are a member of the carbon nanomaterial family with numerous applications. Aggregation is one of the barriers to the performance of C-dots, which causes luminescence quenching, surface area decreases, etc.

Polysaccharide-based C-dots and polysaccharide/C-dot nanocomposites: fabrication strategies and applications.

C-dots are a new class of materials with vast applications. The synthesis of bio-based C-dots has attracted increasing attention in recent years. Polysaccharides being the most abundant natural materials with high biodegradability and no toxicity have been the focus of researchers for the synthesis of C-dots.

Piperine from Black Pepper Decreased the Expression of Intercellular Adhesion Molecule-1 in Macrophages.

Background: Macrophages are the main players involved in inflammation. Intercellular adhesion molecule-1 (ICAM-1) facilitates macrophage polarization prior to extravasation into inflamed tissue. Piperine, a natural product derived from black pepper, possesses useful biological and pharmacological activities.

Therapeutic Efficacy of Mesenchymal Stem Cells and Mesenchymal Stem Cells-derived Neural Progenitors in Experimental Autoimmune Encephalomyelitis.

Background And Objectives: The goal of treatment for MS is to reduce the inflammation and induce the regeneration of degenerated axons. Considering the anti-inflammatory and regenerative capacity of mesenchymal stem cell (MSCs), in this study the therapeutic efficacy of allogeneic MSCs and MSCs-derived neural progenitor cells (MSCs-NPs) was investigated in cellular therapy of chronic experimental autoimmune encephalomyelitis (EAE).

Methods And Results: MSCs, MSCs-NPs and MSCs＋MSCs-NP were administered intravenously to EAE mice on days 22, 29, and 36 post immunization.